Key result
High circulating levels of ET-1, big ET-1, and CT-proET-1 were significantly associated with increased risk of adverse outcomes in heart failure patients (pooled RRs 2.22, 2.47, and 2.27).
Why the study?
Are high plasma levels of ET-1, big ET-1, and CT-proET-1 associated with poor prognosis and mortality in patients with heart failure?
Population
18,497 patients with heart failure across 32 studies
Comparison
High plasma levels of endothelin-1, big ET-1… vs Lower plasma levels of ET-1, big ET-1, and…
Design
Meta-analysis
Authors
Loading...
May aid HF risk stratification; reinforces prognostic value of ET-1 markers but leaves therapeutic implications open.
Meta-Analysis (n=18,497)
Are high plasma levels of ET-1, big ET-1, and CT-proET-1 associated with poor prognosis and mortality in patients with heart failure?
Effect estimate: RR 2.22 (95% CI 1.82-2.71)
p-value: p=<0.001
Increased plasma levels of ET-1, big ET-1, and CT-proET-1 are significantly associated with poor prognosis and higher mortality in patients with heart failure.
Zhang et al. (2017) conducted a meta-analysis in Heart failure (n=18,497). High plasma endothelin-1 (ET-1) vs. Low plasma endothelin-1 (ET-1) was evaluated on Adverse outcomes (death, heart transplant, or HF hospitalization) (RR 2.22, 95% CI 1.82-2.71, p=<0.001). High circulating levels of ET-1, big ET-1, and CT-proET-1 were significantly associated with increased risk of adverse outcomes in heart failure patients (pooled RRs 2.22, 2.47, and 2.27).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: